This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOAbout ABRYSVOEfficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesMaternal RSV Vaccine PlannerHealth Plan CoverageRequest A RepEventsMaterialsVideos
Prescribing InformationIndications Older AdultPatient Site

Maternal RSV Vaccine Planner

Maternal RSV Vaccine Planner

Help protect infants against RSV from birth through 6 months via maternal immunization. 1

For eligible patients, this tool calculates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation 1,2*

ACOG supports the CDC recommendation for maternal RSV vaccination. 2.3*

Scroll down to use tool

Fill out the information below to see if/when ABRYSVO can be given.

Estimated pregnancy due date †

/ /

ZIP code †


Personal information will be stored in accordance with Pfizer's privacy policy.

†Required field.

ACOG supports the CDC recommendation for maternal RSV vaccination. 2.3*

Maternal RSV Vaccine Planner

Results

Based on the estimated due date of 02/22/2025 in ZIP code 83354, will be at the indicated gestation age for ABRYSVO®:

Based on the estimated due date of 02/22/2025 in ZIP code 83354 the pregnant individual's vaccination window for ABRYSVO® falls outside of the September through January seasonal CDC guidance. 1,2*

Based on the estimated due date of 02/22/2025 in ZIP code 83354, wil be at the indicated gestation age for ABRYSVO®:

From 01/02/2025 Through 01/31/2025

Consider discussing RSV prevention options that may be available for infants after birth.

The pregnant individual's vaccination window of 5 WEEKS falls within 32 through 36 weeks gestation AND the September through January seasonal CDC guidance. 1,2*

The pregnant individual's vaccination window of 5 WEEKS falls within 32 through 36 weeks gestation AND the September through January seasonal CDC guidance. 1,2*

The pregnant individual wil be at 32 through 36 weeks gestation outside of September through January. However, your location may have different RSV seasonality compared to most regions of the US.* Please consult your state, local, or territorial guldance on the timing of ABRYSVO vaccination. 1,2

Some of the time that this pregnant individual is between 32 through 36 weeks gestation occurs within the September through January vaccination window recommended by the CDC. Your location may have different RSV seasonality compared to most regions of the US. * Please consult your state, local, or territorial guidance on the timing of ABRYSVO vaccination. 1,2

Vaccination window

Inside CDC-recommended season for maternal RSV vaccination

Indicated vaccination window

Outside CDC-recommended season for maternal RSV vaccination in most regions of the US

Don't miss the vaccination window for ABRYSVO ®. Mark these days on the patient's records and print a reminder for the patient.

The CDC recommends seasonal administration (September through January) of ABRYSVO except in regions where RSV seasonality differs (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, US-affiliated Pacific Islands, US Virgin Islands) and may have different administration guidelines. 2

Infants 6 months and younger are at the highest risk of RSV hospitalization 4

ReferencesABRYSVO is CDC-recommended for pregnant persons as a one-time dose at 32 weeks and 0 days’ through 36 weeks and 6 days’ gestation, using seasonal administration (from September through January in most regions of the US), for prevention of RSV-associated LRTI in infants aged <6 months. In jurisdictions with RSV seasonality that differs (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, US-affiliated Pacific Islands, US Virgin Islands), providers should follow state, local, or territorial guidance on timing of ABRYSVO.2ACOG=American College of Obstetricians and Gynecologists; CDC=Centers for Disease Control and Prevention; LRTI=lower respiratory tract infection;
RSV=respiratory syncytial virus. 

References:

References:ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; August 2024.Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115-1122.American College of Obstetricians and Gynecologists. Maternal Respiratory Syncytial Virus Vaccination Practice Advisory. September 2023. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccinationParikh RC, McLaurin KK, Margulis AV, et al. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017;6(4):477-486. doi:10.1007/s40121-017-0167-9

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-1727
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
 
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%) 
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO. IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV